Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
Código da empresaORGO
Nome da EmpresaOrganogenesis Holdings Inc
Data de listagemDec 02, 2016
Fundado em2018
CEOMr. Gary S. Gillheeney, Sr.
Número de funcionários869
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 02
Endereço85 Dan Rd
CidadeCANTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02021-2810
Telefone17815750775
Sitehttps://investors.organogenesis.com
Código da empresaORGO
Data de listagemDec 02, 2016
Fundado em2018
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados